Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reiterated by equities research analysts at Wells Fargo & Co in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports.
Several other analysts also recently commented on CRSP. Needham & Company LLC reissued a “buy” rating and issued a $62.00 price objective on shares of Crispr Therapeutics in a research note on Wednesday, July 31st. Barclays increased their price objective on Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Canaccord Genuity initiated coverage on Crispr Therapeutics in a research note on Friday, July 26th. They issued a “buy” rating and a $72.00 price objective for the company. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of Crispr Therapeutics in a research note on Monday, October 21st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $68.54.
Shares of Crispr Therapeutics stock opened at $67.42 on Tuesday. The company has a market cap of $3.14 billion, a PE ratio of -19.60 and a beta of 3.15. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The business has a 50 day moving average price of $45.26 and a 200-day moving average price of $45.11. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, research analysts anticipate that Crispr Therapeutics will post 0.64 EPS for the current year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 21.40% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of CRSP. NEXT Financial Group Inc increased its position in shares of Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares during the last quarter. Benjamin Edwards Inc. increased its position in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $26,000. US Bancorp DE increased its position in shares of Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after acquiring an additional 526 shares during the last quarter. Finally, BSW Wealth Partners purchased a new stake in shares of Crispr Therapeutics during the second quarter valued at approximately $39,000. 50.50% of the stock is owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What does an inverted yield curve signify?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.